Supplementary Figures 1 - 7 from The Endogenous Tryptophan Metabolite and NAD<sup>+</sup> Precursor Quinolinic Acid Confers Resistance of Gliomas to Oxidative Stress

PDF file - 164K, Supplemental Figure 1: IDO-1 expression in glioma tissue sections. Supplemental Figure 2: Viability determined by MTT assay in T325 primary glioma cells (a) and HA1800 primary astrocytes (b). Supplemental Figure 3: NAD+ levels in malignant glioma cells A172 and human astrocytes after application of FK866, A172 P=0.006, astrocytes P=0.002 (a). NAD+ levels in A172 glioma cells treated with TMZ, P=0.009 (b). NAD+ levels in A172 cells treated with FK866 and supplemented with QA (c). Supplemental Figure 4: NAPRT expression in normal brain and glioma tissue WHO grade IIIV (28), P=0.86. Supplemental Figure 5: Immunoblot of QPRT in shQPRT and control A172 cells (a). CD68/3-HAO co-expression in tissue sections of glioblastoma (b). Test for CD14 expression in A172 and human astrocytes (c), QPRT expression in additional primary cells (c). Supplemental Figure 6: Survival analysis of glioblastoma patients with tumors expressing high or low levels of QPRT (28). Supplemental Figure 7: Detection of QA and picolinic acid (PA) via GC/MS in supernatant of microglia, glioma cells lines, human astrocytes and glioma-initiating cells T325.